Candida vulvovaginitis medical therapy: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
m (Bot: Removing from Primary care)
Line 24: Line 24:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Disease]]
[[Category:Primary care]]
[[Category:Up-To-Date]]


[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Gynecology]]
[[Category:Gynecology]]
[[Category:Obstetrics]]
[[Category:Obstetrics]]

Revision as of 20:47, 29 July 2020

Candida vulvovaginitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Candidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

Other Imagining Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Candida vulvovaginitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Candida vulvovaginitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Candida vulvovaginitis medical therapy

CDC on Candida vulvovaginitis medical therapy

Candida vulvovaginitis medical therapy in the news

Blogs on Candida vulvovaginitis medical therapy

Directions to Hospitals Treating Candidiasis

Risk calculators and risk factors for Candida vulvovaginitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Antifungal agents are indicated in candidiasis. Commonly used drugs include Amphotericin, Clotrimazole, Nystatin, Fluconazole and Ketoconazole. It is important to consider that Candida species are frequently part of the human body's normal oral and intestinal flora. Candidiasis is occasionally misdiagnosed by medical personnel as bacterial in nature, and treated with antibiotics against bacteria. This can lead to eliminating the yeast's natural competitors for resources, and increase the severity of the condition.

Medical Therapy

According to, 2016 Update by the Infectious Diseases Society of America medical therapy for Candida vulvovaginitis includes[1]:

  • Uncomplicated Candida Vulvovaginits:
    • 1st line :Any topical antifungal agents can be used and all of them have equal efficacy
    • Alternative : Single 150mg dose of oral fluconazole is recommended
  • Severe acute Candida vulvovaginitis:
    • 1st line: Oral fluconazole 150mg, given every 72 hours for a total of 2 or 3 doses
  • Candida glabrata: When unresponsive to oral azoles
    • 1st line: Topical intravaginal boric acid administered in a gelatin capsule, 600mg daily for 14 days
    • 2nd line: Nystatin intravaginal suppositories, 100,000 units daily for 14 days
    • 3rd line: Topical 17% flucytosine cream alone or in combination with amphotericin B cream daily for 14 days
  • Recurring vulvovaginal candidiasis:
    • 1st line: 10 to 14 days of induction therapy with a topical agent or oral fluconazole, followed by fluconazole, 150mg weekly for 6 months

Candida Vulvovaginitis in HIV positive women

  • Treatment of symptomatic Candida vulvovaginitis in HIV-positive women is similar to HIV-negative individuals.

References

  1. Pappas, Peter G.; Kauffman, Carol A.; Andes, David R.; Clancy, Cornelius J.; Marr, Kieren A.; Ostrosky-Zeichner, Luis; Reboli, Annette C.; Schuster, Mindy G.; Vazquez, Jose A.; Walsh, Thomas J.; Zaoutis, Theoklis E.; Sobel, Jack D. (2015). "Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases: civ933. doi:10.1093/cid/civ933. ISSN 1058-4838.